Subcutaneous injection technique — my results so far

anna.melb_AU said:

The mechanism that matters here is not stomach emptying, it is central.

Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.

Adding the clinical framing, because it changes how the question reads.

HPLC_Greg said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

newstart_MO said:

Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

Pushing back on newstart_MO here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

That is the short version; the long version is somebody else's post.

One concrete data point for the thread. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

Moderator note: the sourcing question belongs in the vendor section and has been split out. Report rather than reply if it drifts again.